Medical technology firm, Biolase Technology has secured a new US patent to utilize its laser technologies for treatment of farsightedness.
The new patent covers the laser-tunneling procedure that reduces the impact of presbyopia and allows the eye to refocus both at short and long distances.
At present, Biolase has 20 pending and 7 issued US and worldwide patents in the four portfolios in the ophthalmology field. The major products of the company are dental laser devices that can be used for a variety of dental procedures such as cosmetic and other surgeries.
According to Biolase Technology, the company’s laser technology differs from other laser procedures utilized for treating farsightedness. Biolase’s laser technology restores usual ‘accommodative’ function and does not modify the lens or cornea, thus enhancing distance, intermediary and near vision.
Federico Pignatelli, Chief Executive Officer and Chairman at Biolase Technology, said that the company’s laser technologies could be used in dental and other medical application including ophthalmology. He further said that the combination of new patent and the company’s lasers, which have been approved by FDA for using with ocular tissue and the tissue close to the orbit and eye, enable it as a viable partner for ophthalmic firms requiring novel expertise and technology to enter the ophthalmology market.
Source: http://www.biolase.com